Headquartered in Cambridge, Horizon is a provider of CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings which are designed to help scientists better understand gene function, genetic disease drivers and biotherapeutics delivery.
The company has 400 employees across the UK, the US and Japan; and reported revenue from continuing operations of $75.5m (£58.3m) in 2019.
PerkinElmer says the acquisition will expand its portfolio of automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. “It will also provide an opportunity to provide important tools for exploring next generation cell engineering and customized cell lines for relevant biological models – important for the future of precision medicine,” notes the company.
PerkinElmer’s discovery and applied genomics solutions feature a range of immunoassay platforms, high content screening (HCS) and in vivo imaging, along with microfluidics, robotic liquid handling technologies and next-generation sequencing library preparation kits.
The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2021.